The Politics of Comparative Effectiveness Research: Lessons from Recent History

Published on Feb 1, 2014in Journal of Health Politics Policy and Law1.839
· DOI :10.1215/03616878-2395199
Corinna Sorenson14
Estimated H-index: 14
(LSE: London School of Economics and Political Science),
Michael K. Gusmano18
Estimated H-index: 18
(Hastings Center),
Adam Oliver19
Estimated H-index: 19
(LSE: London School of Economics and Political Science)
Efforts to support and use comparative effectiveness research (CER), some more successful than others, have been promulgated at various times over the last forty years. Following a resurgence of interest in CER, recent health care reforms provided substantial support to strengthen its role in US health care. While CER has generally captured bipartisan support, detractors have raised concerns that it will be used to ration services and heighten government control over health care. Such concerns almost derailed the initiative during passage of the health care reform legislation and are still present today. Given recent investments in CER and the debates surrounding its development, the time is ripe to reflect on past efforts to introduce CER in the United States. This article examines previous initiatives, highlighting their prescribed role in US health care, the reasons for their success or failure, and the political lessons learned. Current CER initiatives have corrected for many of the pitfalls experienced by previous efforts. However, past experiences point to a number of issues that must still be addressed to ensure the long-term success and sustainability of CER, including adopting realistic aims about its impact, demonstrating the impact of Patient-Centered Outcomes Research Institute (PCORI) and communicating the benefits of CER, and maintaining strong political and stakeholder support.
  • References (41)
  • Citations (11)
📖 Papers frequently viewed together
2 Citations
1 Author (Margaret Francis)
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
The Patient-Centered Outcomes Research Institute . . . shall not develop or employ a dollars per quality adjusted life year (or similar measure that discounts the value of a life because of an individual's disability) as a threshold to establish what type of health care is cost effective or recommended. The Secretary shall not utilize such an adjusted life year (or such a similar measure) as a threshold to determine coverage, reimbursement, or incentive programs under title XVIII. — The Patient ...
183 CitationsSource
#1John K. Iglehart (Patient-Centered Outcomes Research Institute)H-Index: 1
The creation of a public-private institute to direct new comparative effectiveness research represents a challenging new chapter in America’s on-again, off-again support for determining what works in health care.
20 CitationsSource
#1Kavita Patel (New America Foundation)H-Index: 13
The Patient Protection and Affordable Care Act established a new public-private entity for comparative effectiveness research: the Patient-Centered Outcomes Research Institute. The institute is charged with identifying priorities, establishing an agenda, and carrying out comparative effectiveness research. The political process through which the institute was formalized greatly influenced its scope and charge, including the organization’s goals, its unique private-public composition, and its fun...
19 CitationsSource
#1S GerberAlan (Yale University)
#2Eric M. Patashnik (UVA: University of Virginia)H-Index: 13
Last. Conor M. Dowling (Yale University)H-Index: 19
view all 4 authors...
We conducted two national surveys of public opinion about comparative effectiveness research and the integration of findings from the research into clinical practice. The first survey found broad support for using research results to provide information, but less support for using them to allocate government resources or mandate treatment decisions. In addition, the public is willing to consider the use of financial incentives to encourage patients to choose cheaper treatments, if research demon...
20 CitationsSource
#1Steven D. Pearson (Pearson Education)H-Index: 38
#2Peter B. Bach (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 55
Medicare must find new ways to achieve cost control without limiting access to beneficial services. We propose a payment model incorporating comparative effectiveness research to encourage Medicare to pay equally for services that provide comparable patient outcomes. The model would include higher payments for services demonstrated by adequate evidence to provide superior health benefits compared to alternative options. New services without such evidence would receive usual reimbursement rates f...
75 CitationsSource
#1James C. Robinson (University of California, Berkeley)H-Index: 40
Comparative effectiveness research has been promoted as a way to control health care costs, but there has been less discussion of the mechanisms through which new evidence actually will influence physician practice, patient preference, and manufacturer investment. Public and private insurers use conditional coverage, consumer cost sharing, provider contracting, and drug payment policies to manage and direct the flow of resources into the health care system. This paper examines how each of these ...
7 CitationsSource
#1Kristin L. Carman (AIR: American Institutes for Research)H-Index: 12
#2Maureen Maurer (AIR: American Institutes for Research)H-Index: 6
Last. Karen O. MarloH-Index: 1
view all 7 authors...
We undertook focus groups, interviews, and an online survey with health care consumers as part of a recent project to assist purchasers in communicating more effectively about health care evidence and quality. Most of the consumers were ages 18–64; had health insurance through a current employer; and had taken part in making decisions about health insurance coverage for themselves, their spouse, or someone else. We found many of these consumers’ beliefs, values, and knowledge to be at odds with ...
101 CitationsSource
#1Bryan R. LuceH-Index: 27
#2Michael DrummondH-Index: 73
Last. Sean D. SullivanH-Index: 65
view all 7 authors...
Context: The terms evidence-based medicine (EBM), health technology assessment (HTA), comparative effectiveness research (CER), and other related terms lack clarity and so could lead to miscommunication, confusion, and poor decision making. The objective of this article is to clarify their definitions and the relationships among key terms and concepts. Methods: This article used the relevant methods and policy literature as well as the websites of organizations engaged in evidence-based activiti...
84 CitationsSource
Background and objective: Studies from the US and Canada observed changes in antihypertensive prescribing patterns in accordance with Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study findings immediately after the study's publication, but little is known about the impact of ALLHAT in Italy. The objective of this study was to examine antihypertensive prescribing patterns in Regione Emilia-Romagna (RER), Italy, following the publication of the ALLHAT main ...
14 CitationsSource
7 CitationsSource
Cited By11
2 CitationsSource
#1Ann C. Keller (University of California, Berkeley)H-Index: 8
#2Robin Flagg (University of California, Berkeley)H-Index: 1
Last. Suhasini RaviH-Index: 1
view all 4 authors...
1 CitationsSource
#1Philip Rocco (Marquette University)H-Index: 8
#2Andrew S. Kelly (CSUEB: California State University, East Bay)H-Index: 4
Last. Ann C. Keller (University of California, Berkeley)H-Index: 8
view all 3 authors...
In the eight years since the passage of the Patient Protection and Affordable Care Act (ACA), state governments have remained critical sites of contention over the law. Intense partisan conflict over ACA implementation has raised questions about traditional theories of intergovernmental relations, which posit that federal–state cooperation depends largely on policy design. Yet, few studies have examined how partisanship, as well as other important factors, shape state policy innovations under th...
5 CitationsSource
1 CitationsSource
#1Karen J. Maschke (Hastings Center)H-Index: 11
#2Michael K. Gusmano (RU: Rutgers University)H-Index: 18
ABSTRACTWe examine a recent dispute regarding the Centers for Medicare and Medicaid Services’ (CMS) refusal to unconditionally pay for amyloid positron emission tomography (PET) imaging for Medicare beneficiaries being assessed for Alzheimer’s disease. CMS will only pay for amyloid PET imaging when patients are enrolled in clinical trials that meet certain criteria. The dispute reflects CMS’s willingness in certain circumstances to require effectiveness evidence that differs from the Food and Dr...
#1Mark Schlesinger (Yale University)H-Index: 37
#2Rachel Grob (UW: University of Wisconsin-Madison)H-Index: 10
Policy Points: Effectively addressing low-value care calls for engaging the public, including the one-third of Americans who currently cannot envision benefits from avoiding low-value care. Public awareness of and response to low-value care can be enhanced through revised media messaging. These efforts are more effective if they emphasize health risks rather than the financial costs associated with unnecessary tests and treatments. Long-term robust public support for addressing low-value care ma...
13 CitationsSource
#1Karen J. Maschke (Hastings Center)H-Index: 11
#2Michael K. Gusmano (RU: Rutgers University)H-Index: 18
: The controversy over patients' access to stem cell interventions is familiar to scholars of the drug regulatory system and the politics of evidence-based medicine. What counts as evidence of a biomedical intervention's safety and effectiveness? Who should define and assess safety and effectiveness, and how? In the first section of the paper we describe the types of stem cells that may be therapeutically effective. We then describe how the US Food and Drug Administration asserted regulatory aut...
4 CitationsSource
#1Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 44
#2Jerry Avorn (Brigham and Women's Hospital)H-Index: 112
Last. Ameet Sarpatwari (Brigham and Women's Hospital)H-Index: 13
view all 3 authors...
Importance The increasing cost of prescription drugs in the United States has become a source of concern for patients, prescribers, payers, and policy makers. Objectives To review the origins and effects of high drug prices in the US market and to consider policy options that could contain the cost of prescription drugs. Evidence We reviewed the peer-reviewed medical and health policy literature from January 2005 to July 2016 for articles addressing the sources of drug prices in the United State...
204 CitationsSource
#1Mildred Z. Solomon (Harvard University)H-Index: 20
#2Michael K. Gusmano (Hastings Center)H-Index: 18
Last. Karen J. Maschke (Hastings Center)H-Index: 11
view all 3 authors...
Engaging patients and the public with evidence is an ethical imperative because engagement is central to respect for persons and will likely improve health outcomes, facilitate the stewardship of resources, enhance prospects for justice, and build public trust. However, patient and public engagement is also morally complex, because evidence alone is never definitive. As patients and the public engage with evidence, value conflicts will arise and must be managed to achieve trustworthy decision ma...
18 CitationsSource